Is Kyntra Bio, Inc. (NASDAQ:KYNB) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Kyntra Bio, Inc. at current levels.
A $28M micro-cap sitting on positive free cash flow, a CD46 ADC asset, and a rebrand the market hasn't digested.
Where KYNB is headed
Kyntra Bio is what's left after FibroGen spent a decade burning through capital chasing Roxadustat into walls the FDA wouldn't let it through. The rebrand in January was cosmetic on the surface, substantive underneath. The company shed the FibroGen baggage, refocused on FG-3246 (the CD46-targeted antibody-drug conjugate for metastatic castration-resistant prostate cancer), and is now sitting on roughly $27M in free cash flow against a $28M market cap. That ratio alone should make any biotech investor stop and re-read the screen. The market is treating this as a dead Roxadustat story. It isn't.
Read the full Compass Direction on KYNB
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $6.88).
See the full KYNB analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Kyntra Bio, Inc. (NASDAQ:KYNB) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Kyntra Bio, Inc. at current levels. A $28M micro-cap sitting on positive free cash flow, a CD46 ADC asset, and a rebrand the market hasn't digested.
What is KYNB's Compass Score?
Kyntra Bio, Inc. scores 74/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for KYNB?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the KYNB page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.